| Species |
Human |
| Protein Construction |
KIR2DL1 (His22-Arg242)
Accession # P43626 |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
27.1 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 48-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
KIR2DL1 (2DL1, formerly NKAT1, designated CD158a) is a 348 amino acid (aa) type I transmembrane glycoprotein that belongs to the human killer cell Ig-like receptor (KIR) family.KIR2DL1 is a receptor on natural killer (NK) cells for some HLA-C alleles such as w4 and w6. Inhibits the activity of NK cells thus preventing cell lysis. |
| Synonyms |
CD158Ankat1; CD158A; cl-42; KIR2DL1; NKAT; NKAT-1; p58.1; KIR-K64; KIR221; KIR2DL1/KIR2DS5 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
